Nov 1, 2017

Edixomed Granted US and EU Patent Protection for Their Nitric Oxide Generating Treatment System Edixomed have been granted Intellectual Property protection for their nitric oxide generating treatment system in both the EU and USA. The priority date for the patents is 2014, therefore giving Edixomed IP protection for a further 17 years until 2034. The patents cover a platform of treatment systems that includes the system used in ProNOx1, the 148-wound randomised controlled study in diabetic foot ulcers.

30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.

30 TECHNOLOGY Therapeutic Nitric Oxide